Articles By Wayne Koberstein, Executive Editor

Companies To Watch: Equillium
Equillium is keeping a close eye on the COVID-19 challenge, but sticking to acute GVHD, uncontrolled asthma, and lupus nephritis as primary inflammation targets.  Continue Reading..
  • The Viral Startup

    ViralClear, formed in March 2020 to obtain a drug whose potential use against COVID-19 already has substantial support in evidence. The company is employing considerable industry expertise to move it into clinical development.

  • Companies To Watch: Spring Bank Pharmaceuticals

    Spring Bank Pharmaceuticals is continuing clinical programs during the COVID-19 challenge and advancing novel approaches to cancer, inflammation, and viruses.

  • A European Model For Innovative Bio Funding

    Challenge breeds creativity, and a fresh example of that has emerged in Germany’s Ruhr Valley, with the company Abalos Therapeutics and the unique funding model that supported its launch.

  • Companies To Watch: argenx

    Argenx is developing new antibody therapeutics for immunological diseases in the neuromuscular, hematology, oncology, and other areas. The company has a full pipeline of candidates and indications.

  • Companies To Watch: Neurana

    This 10-person startup in San Diego is aiming for muscle-spasm relief without sedation in a purified drug.

  • Making Progress On A Micro-Budget

    Started in 2017, Eikonizo Therapeutics has led an uphill battle to getting funding for its pipeline that includes drugs for ALS and Alzheimer’s, among other neurodegenerative diseases.

  • A New Life In Bio

    This unlikely CEO’s experience offers some valuable lessons in founding and scaling up a biotech company, particularly one in a nascent space such as regenerative medicine.

  • Companies To Watch: Adaptive Phage Therapeutics

    Adaptive Phage Therapeutics has created a large catalog of bacteria-killing viruses combined with a diagnostic test to identify and target specific bacterial strains infecting individual patients.

  • A Global Biotech Player From Down Under

    “The other part of being a CEO of a listed company is all about investors, and that was an uphill learning curve for me because I’d never dealt with that aspect,” explains Imugene’s CEO Leslie Chong.

  • Companies To Watch: Imago BioSciences

    In developing a new drug for MPN diseases, Imago is entering a space where two potential competitors, Jakafi and Inrebic, both JAK (janus associated kinase) inhibitors, are already on the market.

  • Companies To Watch: Scynexis

    Scynexis is creating multiple development programs and a new class of antifungals — all in a single, and singular, drug.

  • Competing Interests Complicate FDA Reform

    With input from two long-time observers of the biopharma industry and its U.S. regulator, this article covers a cross-section of opinions regarding trends and proposals for improving the FDA review process.

  • Crossing Over From Supplier To Sponsor

    What can make a company decide to enter new therapeutic entities into clinical development after decades as a dedicated supplier to bio research labs? Here we explain the reasons and implications of ArunA Bio’s decision.

  • Taking It All The Way To Phase 3 Clinical Trials

    Pluristem offers one example of how a new company in drug development can build the needed infrastructure to maintain its independence as a sponsor.

wayne koberstein

Wayne Koberstein

Wayne Koberstein is a 30-year veteran of the publishing industry, with extensive experience in publishing, communications, and business development. Wayne has interviewed and profiled more than 300 top executives in pharmaceutical companies, as well as major regulatory and health care leaders, around the world. He has also created special media projects and conferences, in addition to serving widely as speaker, moderator, and advisor for industry meetings.